Startseite › Kolorektales Karzinom › Wisconsin › Madison
Klinische Studien zu Kolorektales Karzinom in Madison, WI
23 Studien zu Kolorektales Karzinom suchen Teilnehmer an Standorten in und um Madison (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
Teilnehmer gesuchtPhase 2
- University of Wisconsin, Madison
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Teilnehmer gesuchtPhase 1/2
- University of Wisconsin Carbone Cancer Center, Madison
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Teilnehmer gesuchtPhase 2
- UW Health Carbone Cancer Center, Madison
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- Wisconsin Institute for Medical Research, Madison
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Teilnehmer gesuchtPhase 1/2
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Teilnehmer gesuchtPhase 1/2
- University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0293), Madison
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Teilnehmer gesuchtPhase 3
- William S. Middleton Memorial VA, Madison
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Teilnehmer gesuchtPhase 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Teilnehmer gesuchtPhase 2
- Research Site, Madison
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Teilnehmer gesuchtPhase 1
- University of Wisconsin - Carbone Cancer Center, Madison
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
Teilnehmer gesuchtPhase 2
- University of Wisconsin Carbone Cancer Center, Madison
An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis
Teilnehmer gesuchtPhase 2
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Teilnehmer gesuchtPhase 3
- Clinical Study Site, Madison
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
Teilnehmer gesuchtPhase 1
- Univ of Wisconsin-Madison, Madison
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Teilnehmer gesuchtPhase 1
- University of Wisconsin - Carbone Cancer Center, Madison
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1/2
- University of Wisconsin, Carbone Cancer Center, Madison
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- University of Wisconsin- Madison, Madison
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Teilnehmer gesuchtPhase 1/2
- GSK Investigational Site, Madison
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Teilnehmer gesuchtPhase 1/2
- University of Wisconsin, Madison
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- University of Wisconsin (Carbone Cancer Center), Madison
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Teilnehmer gesuchtBeobachtungsstudie
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Teilnehmer gesuchtPhase 4
- University of Wisconsin, Madison
Kolorektales Karzinom-Studien in anderen Städten
- Houston, TX102 Studien
- New York City, NY78 Studien
- Nashville, TN69 Studien
- Boston, MA63 Studien
- Los Angeles, CA59 Studien
- Arlington, VA52 Studien
- St. Louis, MO50 Studien
- San Antonio, TX46 Studien
- Philadelphia, PA44 Studien
- Grand Rapids, MI40 Studien
- Baldwin Park, CA37 Studien
- Chicago, IL34 Studien
Weitere Studien in Madison
- Prostatakrebs29 Studien
- Brustkrebs22 Studien
- Metastasierender Krebs21 Studien
- Akute myeloische Leukämie16 Studien
- Nichtkleinzelliges Lungenkarzinom16 Studien
- Melanom15 Studien
- Krebs (alle Arten)14 Studien
- Eierstockkrebs13 Studien
- Magenkrebs11 Studien
- Bauchspeicheldrüsenkrebs10 Studien
- Lungenkrebs10 Studien
- Multiples Myelom9 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.